Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals, LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality. Comorbidities are a common consequence of sickle cell disease, chemotherapy, atherosclerosis, diabetes and many other diseases.
  • The company's lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders caused by ischemia, hypoxia and/or hemolysis
  • Prolong has a long-acting 3rd generation biologic in clinical development for the treatment of anemia, a comorbidity common with chronic kidney disease and cancer chemotherapy
  • Other products are also in development for comorbidities that result from diseases such as cardiovascular disorders and cancer



Originally established in 2005 as a research lab, Prolong has emerged as a mature privately held biotech company. Led by a team of successful pharmaceutical executives, Prolong has multiple clinical development programs and large scale cGMP manufacturing facilities in production.


The Prolong leadership has led and been associated with a number of successful pharmaceutical and biotechnology companies. The team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide.